Skip to content

Catheter Ablation Therapy for Persistent Atrial Fibrillation

Catheter Ablation Therapy for Persistent Atrial Fibrillation: Value of Additional Linear Ablation on Left Atrial Anterior Wall

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02892162
Acronym
CLEAR-AF
Enrollment
214
Registered
2016-09-08
Start date
2016-08-31
Completion date
2019-07-31
Last updated
2016-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent Atrial Fibrillation

Keywords

atrial fibrillation, catheter ablation

Brief summary

Use of catheter ablation for persistent atrial fibrillation (PerAF) remains controversial due to unsatisfactory long-term success rates (15% - 28.4%). The investigators' previous study indicated that the upper area of the left atrium (LA) plays an important role in PerAF, with the LA roof and mitral isthmus appearing to serve as main substrate in progression from PAF to PerAF and maintenance of fibrillatory activities. The investigators therefore hypothesized that AF should not be initiated or sustained if the latter crucial regions for AF maintenance are abolished. This study aimed to describe the efficacy and safety of additional linear ablation on the left atrial anterior wall for PerAF.

Detailed description

Although studies and guidelines have helped establish catheter ablation as preferred treatment for patients suffering from paroxysmal atrial fibrillation (PAF), use of catheter ablation for persistent atrial fibrillation (PerAF) remains controversial due to unsatisfactory long-term success rates (15% - 28.4%). The investigators' study indicated that the upper area of the left atrium (LA) plays an important role in PerAF, with the LA roof and mitral isthmus appearing to serve as main substrate in progression from PAF to PerAF and maintenance of fibrillatory activities. The investigators therefore hypothesized that AF should not be initiated or sustained if the latter crucial regions for AF maintenance are abolished. This was confirmed using a stepwise pure linear ablation protocol, consisting of a line across the LA roof and extending along the anterior wall of pulmonary veins (PV) antrum to mitral valve annulus (MVA) without PV isolation; the approach appeared safe and effective with long-term (5.2 years) follow-up success rate of 40% for PerAF. This study will evaluate efficacy and safety of circumferential pulmonary vein isolation (CPVI) + LA roof linear ablation + LA anterior wall (LAAW) linear ablation combined with high density mapping and contact force sensing techniques for perAF. This study is expected to provide a practical and guided catheter ablation strategy with maximized safety and efficacy through use of contact force sensing technique, which will be accepted by other qualified electrophysiology laboratories.

Interventions

PROCEDUREAdditional LAAW linear ablation

Additional linear ablation on LAAW using ThermoCool SmartTouch ablation catheter.

Sponsors

Beijing Hospital
CollaboratorOTHER_GOV
First Affiliated Hospital, Sun Yat-Sen University
CollaboratorOTHER
Tianjin Medical University General Hospital
CollaboratorOTHER
Wuhan Asia Heart Hospital
CollaboratorOTHER
First Affiliated Hospital of Kunming Medical University
CollaboratorOTHER
China National Center for Cardiovascular Diseases
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

\- The main inclusion criterion is patients suffering from drug refractory persistent atrial fibrillation and referred to catheter ablation therapy. Persistent AF is defined as continuous AF for over 7 days, or lasting no more than 7 days but requiring pharmacological or electrical cardioversion.

Exclusion criteria

1. Patients without spontaneous ongoing AF at the beginning of the procedure; 2. Age: \<18 years or \>70 years; 3. LA size \> 55mm measured on echocardiogram; 4. Previous AF ablation history including surgical ablation; 5. Documented LA thrombus; 6. Severe pulmonary diseases; 7. Previous cardiac surgical history.

Design outcomes

Primary

MeasureTime frameDescription
AF recurrenceFrom August, 2016 to July 2019. The overall Time Frame for AF recurrence is being assessed up to 36 months.Freedom from AF at 1 year without any anti-arrhythmic drugs. Recurrent AF is defined as documented AF (through 12-lead ECG or Holter) period lasting \>30 seconds after a 3-month blanking period.

Secondary

MeasureTime frame
Acute success rate of AF termination during ablation procedureFrom August, 2016 to July 2017. The overall Time Frame for AF termination during ablation procedure is being assessed up to 12 months.
Frequency of complicationsFrom August, 2016 to July 2017. The overall Time Frame for frequency of complications is being assessed up to 12 months.
Average radiation exposureFrom August, 2016 to July 2017. The overall Time Frame for average radiation exposure is being assessed up to 12 months.
Frequency of redo proceduresFrom August, 2016 to July 2019. The overall Time Frame for frequency of redo procedures is being assessed up to 12 months.

Other

MeasureTime frame
Average ablation time and procedure timeFrom August, 2016 to July 2017. The overall Time Frame for average ablation time and procedure time are being assessed up to 12 months.

Countries

China

Contacts

Primary ContactYan Yao, MD,PhD
ianyao@263.net.cn+86-13901121319
Backup ContactLingmin Wu, MD,PhD
wlmxt2008@126.com+86-18810488351

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026